Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
26.89
+1.49 (5.87%)
At close: Dec 5, 2025, 4:00 PM EST
26.88
-0.01 (-0.04%)
After-hours: Dec 5, 2025, 7:59 PM EST
Capricor Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 11.13 | 22.27 | 25.18 | 2.55 | 0.24 | 0.31 | |
| Revenue Growth (YoY) | -52.08% | -11.55% | 886.81% | 941.85% | -21.06% | -69.13% | |
| Cost of Revenue | 75.88 | 49.97 | 36.45 | 21.82 | 13.57 | 8.46 | |
| Gross Profit | -64.75 | -27.7 | -11.27 | -19.27 | -13.33 | -8.15 | |
| Selling, General & Admin | 21.94 | 14.87 | 12.81 | 10.43 | 7.61 | 5.54 | |
| Operating Expenses | 21.94 | 14.87 | 12.81 | 10.43 | 7.61 | 5.54 | |
| Operating Income | -86.68 | -42.56 | -24.08 | -29.7 | -20.94 | -13.69 | |
| Interest & Investment Income | 4.92 | 2.2 | 1.73 | 0.52 | 0.06 | 0.03 | |
| Other Non Operating Income (Expenses) | 0.04 | 0.01 | 0.07 | - | - | - | |
| EBT Excluding Unusual Items | -81.72 | -40.35 | -22.28 | -29.18 | -20.88 | -13.66 | |
| Gain (Loss) on Sale of Assets | -0.27 | -0.11 | -0.01 | -0.03 | -0.01 | - | |
| Other Unusual Items | - | - | - | 0.19 | 0.87 | - | |
| Pretax Income | -81.99 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | |
| Net Income | -81.99 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | |
| Net Income to Common | -81.99 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | |
| Shares Outstanding (Basic) | 45 | 35 | 27 | 25 | 23 | 16 | |
| Shares Outstanding (Diluted) | 45 | 35 | 27 | 25 | 23 | 16 | |
| Shares Change (YoY) | 43.02% | 31.52% | 9.06% | 6.34% | 48.28% | 319.55% | |
| EPS (Basic) | -1.81 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | |
| EPS (Diluted) | -1.81 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | |
| Free Cash Flow | -68.38 | -41.53 | -27.64 | 1.56 | -18.01 | -10.6 | |
| Free Cash Flow Per Share | -1.51 | -1.18 | -1.03 | 0.06 | -0.78 | -0.68 | |
| Gross Margin | - | -124.37% | -44.76% | - | - | - | |
| Operating Margin | -778.80% | -191.13% | -95.63% | -1163.93% | -8549.86% | -4412.56% | |
| Profit Margin | -736.62% | -181.71% | -88.52% | -1137.37% | -8175.86% | -4401.94% | |
| Free Cash Flow Margin | -614.30% | -186.50% | -109.79% | 61.02% | -7352.29% | -3417.38% | |
| EBITDA | -84.92 | -41.14 | -23.01 | -29.16 | -20.69 | -13.55 | |
| EBITDA Margin | - | -184.73% | -91.39% | - | - | - | |
| D&A For EBITDA | 1.76 | 1.43 | 1.07 | 0.53 | 0.25 | 0.14 | |
| EBIT | -86.68 | -42.56 | -24.08 | -29.7 | -20.94 | -13.69 | |
| EBIT Margin | - | -191.13% | -95.63% | - | - | - | |
| Revenue as Reported | 11.13 | 22.27 | 25.18 | 2.55 | 0.24 | 0.31 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.